Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chimeron Bio's Immuno-oncology Program is an in vivo gene therapy approach designed to modulate the tumor immune microenvironment (TIME) to restore anti-tumor immune surveillance. The program utilizes the company's proprietary MultiPlex RNA delivery platform, which is based on 'Chaomer' technology—self-assembling RNA nanoparticles. This platform enables the coordinated delivery and expression of multiple genes targeting various immune pathways simultaneously. The therapy is designed to provide weeks-long therapeutic activity from a single administration, featuring precise targeting and enhanced cellular uptake to drive the elimination of cancer cells while potentially overcoming the limitations of traditional systemic immunotherapies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Immuno-oncology Program (Chimeron Bio).